US biotech PureTech Health is to develop therapies that are based on a new theory that neurological diseases such as Alzheimer’s are linked to drainage issues in the brain.
Biogen and Eisai said their latest clinical study confirmed the amyloid hypothesis and might lead to the first drug successfully treating Alzheimer’s disease, instantly bumping their share
